An extension of a pivotal phase 3 trial shows that the functional and anatomic benefits of Eylea HD (aflibercept 8 milligram dose) have staying power in people with neovascular (wet) age-related macular degeneration, according to results presented at the American Society of Retina Specialists annual meeting in Long Beach, California.

At the end of the PULSAR extension trial, with 60 weeks added to the original trial’s 96-week duration, the 208 study participants who switched from a 2-milligram dose of aflibercept to the 8-milligram dose contained in Eylea HD experienced an average improvement of best-corrected visual acuity (BCVA) of 4.6 letters and a decrease in central subfield retinal thickness of 145 micrometers, according to results presented yesterday by David T.W. Wong, M.D., ophth

See Full Page